Heterogeneity & Sample Size Calculator

An I-squared calculator quantifies the proportion of total variability in a set of effect estimates that is attributable to genuine between-study differences rather than within-study sampling error. Introduced by Higgins & Thompson (2002) and codified in the Cochrane Handbook (Higgins et al., 2023), I-squared has become the most widely reported heterogeneity statistic in systematic reviews because it offers an intuitive percentage-based interpretation. Cochrane RevMan, the standard software for Cochrane systematic reviews, reports I-squared alongside Cochran's Q and tau-squared as built-in heterogeneity statistics in every forest plot output. However, I-squared alone does not tell the full story. It is a relative measure that describes the ratio of between-study variance to total variance, and its value depends heavily on the precision of the included studies. Two meta-analyses with identical between-study variance can produce very different I-squared values if one contains large, precise trials and the other contains small, imprecise ones.

This is why a comprehensive heterogeneity test calculator must also report absolute measures. Tau-squared (the between-study variance on the effect-size scale) provides the information that I-squared cannot: how much the true effects actually vary across studies. DerSimonian & Laird (1986) proposed the most commonly used moment-based estimator of tau-squared, and it remains the default in many software packages. More modern estimators, such as restricted maximum likelihood (REML), now recommended as the preferred alternative to DerSimonian-Laird for tau-squared estimation, and the Paule-Mandel estimator, which has been shown to produce improved between-study variance estimates with better coverage properties, produce less biased estimates, particularly when the number of studies is small. Regardless of the estimator, tau-squared feeds directly into the random-effects model weight calculation and into prediction intervals, which describe the range within which the true effect of a future similar study is expected to fall.

The relationship between I-squared and tau-squared is governed by the equation I-squared = tau-squared / (tau-squared + typical within-study variance). This means that meta-analysis heterogeneity can appear low (small I-squared) even when the absolute between-study variance is clinically meaningful, a scenario that arises when the included studies are small and imprecise. Conversely, very large trials can inflate I-squared to alarming levels even when the absolute differences between study effects are trivially small. The Cochrane Handbook recommends interpreting I-squared alongside the confidence interval for I-squared itself, the Q-test p-value, and visual inspection of the forest plot. Prediction intervals, as advocated by IntHout et al. (2016), provide a valuable complement to I-squared by expressing the expected range of true effects in future similar studies, a clinically intuitive measure that can reveal meaningful heterogeneity even when I-squared appears moderate. Our effect size calculator helps ensure that the effect estimates entering your heterogeneity assessment are computed consistently, while the forest plot generator provides the visual context needed to judge whether observed variability is clinically important.

Beyond descriptive statistics, understanding the sources of heterogeneity is often the most valuable part of a meta-analysis. When I-squared exceeds 40-50%, PRISMA 2020 (Page et al., 2021) recommends pre-specified subgroup analyses or meta-regression to explore potential moderators. Study-level characteristics such as risk of bias rating, intervention dose, follow-up duration, and participant demographics may explain why effects differ across studies. As a preliminary step, outlier detection using externally studentized residuals can identify individual studies whose effect sizes fall far from the pooled estimate, flagging potential data errors or genuinely distinct study populations that warrant separate investigation. Our meta-regression data formatter structures moderator data for direct import into R metafor or Stata, while the RoB 2 assessment tool provides the methodological quality ratings that serve as common moderator variables. Together, these tools create a workflow where heterogeneity is not merely reported but actively investigated.

Finally, the tau-squared calculator output has direct implications for sample size planning in future research. When between-study variance is large, even a well-powered individual trial may not resolve the clinical question. What is needed instead is reduction in the sources of heterogeneity through standardized protocols and patient populations. Conversely, when tau-squared is near zero and the summary effect is imprecise, the field needs more or larger studies rather than better-designed ones. By combining I-squared, tau-squared, prediction intervals, and Cochran's Q in a single assessment, researchers gain a multidimensional view of heterogeneity that supports both the interpretation of current evidence and the planning of future research.

REML vs. DerSimonian-Laird: Choosing the Right τ² Estimator

The DerSimonian-Laird (DL) estimator, introduced in 1986, is the most widely used method for estimating between-study variance (τ²) in random-effects meta-analysis. It is a moment-based estimator: it equates the observed Cochran's Q statistic to its expected value under the random-effects model and solves for τ². DL is computationally simple, non-iterative, and has been the default in Cochrane RevMan and most statistical software for decades. However, DL has well-documented limitations. It tends to underestimate τ² when the number of studies is small (fewer than 15–20), which in turn leads to confidence intervals that are too narrow and pooled estimates that appear more precise than they truly are. This negative bias can have real consequences for clinical decision-making, particularly in fields where meta-analyses routinely include only 5–10 studies.

The Restricted Maximum Likelihood (REML) estimator addresses these shortcomings through an iterative likelihood-based approach. REML maximizes a restricted log-likelihood function that accounts for the loss of degrees of freedom from estimating the overall mean, analogous to using n − 1 instead of n in a sample variance calculation. Our implementation uses Fisher scoring, running up to 100 iterations with a convergence threshold of 1×10⁻&sup8;, initialized at the DL estimate to ensure rapid convergence. Simulation studies by Veroniki et al. (2016) and Langan et al. (2019) have shown that REML produces less biased τ² estimates than DL, particularly when the number of studies is small or when studies have unequal sample sizes. The Cochrane Statistical Methods Group and the metafor R package (Viechtbauer, 2010) now recommend REML as the preferred default estimator for random-effects meta-analysis.

When should you use each? For meta-analyses with 20 or more reasonably homogeneous studies, DL and REML typically produce very similar τ² estimates, and the choice is unlikely to affect conclusions. For smaller meta-analyses, which represent the majority of published systematic reviews, REML is the safer choice because it reduces the risk of underestimating between-study variance. When you select REML in this calculator, the DL estimate is displayed alongside for comparison: if the two values are similar, you can be more confident in the result; if they diverge substantially, it signals that the DL estimate may be biased and REML should be preferred. In either case, always report which estimator was used, as recommended by PRISMA 2020 (Page et al., 2021) and the Cochrane Handbook (Higgins et al., 2023).